Literature DB >> 17845507

Chalcone arrests cell cycle progression and induces apoptosis through induction of mitochondrial pathway and inhibition of nuclear factor kappa B signalling in human bladder cancer cells.

Kun-Hung Shen1, Jiunn-Kae Chang, Ya-Ling Hsu, Po-Lin Kuo.   

Abstract

Chalcones (1,3-diphenyl-2-propenone) are cancer preventive food components found in a human diet rich in fruits and vegetables. In this study, we first report the chemopreventive effect of chalcone in two human bladder cancer cell lines: T24 and HT-1376. The results show that chalcone inhibits the proliferation of T24 and HT-1376 cells by inducing apoptosis and blocking cell cycle progression in the G2/M phase. Western blot assay showed that chalcone significantly increases the expression of p21 and p27 proteins, and decreases the levels of cyclin B1, cyclin A and Cdc2, thereby contributing to cell cycle arrest. In addition, chalcone increased the expression of Bax and Bak, but decreased the levels of Bcl-2 and Bcl-X(L) and subsequently triggered mitochondrial apoptotic pathway (release of cytochrome c and activation of caspase-9 and caspase-3). Our study suggests that the induction of mitochondrial pathway and inhibition of the nuclear factor kappa B survival system may play important roles in the antiproliferative activity of chalcone in T24 and HT-1376 cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845507     DOI: 10.1111/j.1742-7843.2007.00120.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  16 in total

1.  New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer.

Authors:  Juan Rodrigues; Claudia Abramjuk; Luis Vásquez; Neira Gamboa; José Domínguez; Bianca Nitzsche; Michael Höpfner; Radostina Georgieva; Hans Bäumler; Carsten Stephan; Klaus Jung; Michael Lein; Anja Rabien
Journal:  Pharm Res       Date:  2010-12-24       Impact factor: 4.200

Review 2.  The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Bharat B Aggarwal
Journal:  Int Immunopharmacol       Date:  2010-12-22       Impact factor: 4.932

3.  Adamantyl arotinoids that inhibit IκB kinase α and IκB kinase β.

Authors:  Paula Lorenzo; María A Ortiz; Rosana Alvarez; F Javier Piedrafita; Angel R de Lera
Journal:  ChemMedChem       Date:  2013-05-07       Impact factor: 3.466

4.  Dietary chalcones with chemopreventive and chemotherapeutic potential.

Authors:  Barbora Orlikova; Deniz Tasdemir; Frantisek Golais; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2011-02-04       Impact factor: 5.523

Review 5.  Chalcone: A Privileged Structure in Medicinal Chemistry.

Authors:  Chunlin Zhuang; Wen Zhang; Chunquan Sheng; Wannian Zhang; Chengguo Xing; Zhenyuan Miao
Journal:  Chem Rev       Date:  2017-05-10       Impact factor: 60.622

Review 6.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

7.  Natural chalcones as dual inhibitors of HDACs and NF-κB.

Authors:  B Orlikova; M Schnekenburger; M Zloh; F Golais; M Diederich; D Tasdemir
Journal:  Oncol Rep       Date:  2012-06-15       Impact factor: 3.906

8.  Selected novel 5'-amino-2'-hydroxy-1, 3-diaryl-2-propen-1-ones arrest cell cycle of HCT-116 in G0/G1 phase.

Authors:  Lalitha Simon; K K Srinivasan; Nitesh Kumar; Neetinkumar D Reddy; Subhankar Biswas; C Mallikarjuna Rao; Sudheer Moorkoth
Journal:  EXCLI J       Date:  2016-01-13       Impact factor: 4.068

9.  Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells.

Authors:  Ewelina Szliszka; Dagmara Jaworska; Małgorzata Ksek; Zenon P Czuba; Wojciech Król
Journal:  Int J Mol Sci       Date:  2012-11-20       Impact factor: 5.923

10.  An Indole-Chalcone Inhibits Multidrug-Resistant Cancer Cell Growth by Targeting Microtubules.

Authors:  Hui Cong; Xinghua Zhao; Brian T Castle; Emily J Pomeroy; Bo Zhou; John Lee; Yi Wang; Tengfei Bian; Zhenyuan Miao; Wannian Zhang; Yuk Yin Sham; David J Odde; Craig E Eckfeldt; Chengguo Xing; Chunlin Zhuang
Journal:  Mol Pharm       Date:  2018-08-09       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.